VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

(1:1econd)

VolitionRx - 2024 Q3 Earnings Analysis

(5:15)

VolitionRx (VNRX) - Cameron Reynolds President \u0026 CEO

(25:12)

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

(3:42)

$VNRX VolitionRx Limited Q3 2024 Earnings Conference Call

(52:9)

VolitionRx Breaks Down Supply Agreement of Nu.Q® Vet Cancer Tests with IDEXX Laboratories

(11:33)

VolitionRx Limited Announces Interim Results from a 680-Subject Clinical Trial in Colorectal Cancer

(5:26)

VolitionRx First Quarter 2024 Financial Results and Business Update

(8:32)

VolitionRx – Commercializing the Nu.Q Vet Cancer Test: Webinar

(36:37)

VolitionRx Discusses $28 Million Licensing Deal with Heska and Focus for 2022

(4:53)

VolitionRx Limited Full Fiscal Year 2022 Financial Results and Business Update

(12:57)

Revolutionizing Healthcare: The Power of VolitionRX's Nucleosomics Platform

(31)

VNRX Stock - VolitionRX Ltd Stock Breaking News Today | VNRX Stock Price Prediction | VNRX Stock

(2:50)

VolitionRX Ltd. (NYSE American: VNRX): Virtual Investor Conferences

(30:10)

Revolutionizing the Diagnosis of Life-altering Diseases 為重疾診斷技術帶來革命性突破 | VolitionRx (NYSE-A: VNRX)

(9:26)

VolitionRx acquires epigenetic reagent company Octamer GmbH

(3:27)

VolitionRx Limited February 2021 Diamond Equity Presentation

(26:32)

VolitionRX

(2:40)

VolitionRx Limited Full Fiscal Year 2023 Financial Results and Business Update

(12:19)

VolitionRx Provides Update on Animal Health Blood Test Program, Licensing Deals and Focus for 2021

(10:16)